


B. Claims

Please amend claims 17-18 as follows. The following is a complete listing of the claims in this application and replaces all earlier versions and all earlier listings of the claims.

1. (Previously Presented) A method of treating hepatitis C in a mammal having symptoms of hepatitis C comprising administering to said mammal an effective amount of a pharmaceutical composition comprising a compound having the structure



and pharmaceutically acceptable salts thereof, wherein:

R₁, R₂, R₃, R₄ and R₅ are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, methoxy, nitro, C₂-C₄ alkenyl, cyano, and trifluoromethyl;

X is O, S, NH, or NR where R is a C₁-C₄ alkyl group;

W is CO₂H or 5- tetrazolyl;

Z is hydrogen or mono-methyl and

G is either OH, F, or hydrogen.

2. (Original) The method of claim 1 wherein the compound is selected from the group consisting of

- 2-[[(2,4-dichlorophenoxy)acetyl]amino} benzoic acid;
- 2-[[(2,5-dimethylphenoxy)acetyl]amino} benzoic acid;
- 2-[[(2-ethoxy-5-Z-(2-propenyl)phenoxy)acetyl]amino} benzoic acid;
- 2-[[(2-bromo-5-fluorophenoxy)acetyl]amino} benzoic acid;
- 2-[[(2-methyl-5-nitrophenoxy)acetyl]amino} benzoic acid;
- 2-[[(2-fluoro-5-methylphenoxy)acetyl]amino} benzoic acid;
- 2-[2-(4-Bromo-phenoxy)-acetylamino]-benzoic acid;
- 2-[2-(3-Bromo-phenoxy)-acetylamino]-benzoic acid;
- 2-[2-(2-Bromo-phenoxy)-acetylamino]-benzoic acid;
- 2-[2-(4-Bromo-phenoxy)-propionylamino]-benzoic acid;
- 2-[2-(4-Bromo-phenylsulfanyl)-acetylamino]-benzoic acid;
- 2-[2-(4-Chloro-phenoxy)-acetylamino]-benzoic acid;
- 2-[2-(4-Fluoro-phenoxy)-acetylamino]-benzoic acid;
- 2-[[(3-chlorophenoxy)acetyl]amino} benzoic acid;
- 2-[[(3-chlorophenoxy)acetyl]amino}-5-fluorobenzoic acid;
- 2-[[(3-chlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
- 2-[[(3,4-dimethylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;
- 2-[[(3-bromophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
- 2-[[(2S)-2-(4-chlorophenoxy)propanoyl]amino} benzoic acid;
- 2-[[(2,3-dichlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
- 2-[[(2,4,5-trichlorophenoxy)acetyl]amino} benzoic acid;

2-{{(2,4-dibromophenoxy)acetyl}amino}benzoic acid;
 2-{{(2-chlorophenoxy)acetyl}amino}benzoic acid;
 2-{{N-(3-bromophenyl)glycyl}amino}benzoic acid;
 2-{{N-(4-bromo-3-chlorophenyl)-N-methylglycyl}amino}benzoic
 acid;
 2-{{(4-chloro-2-methylphenoxy)acetyl}amino}benzoic acid;
 2-{{(5-chloro-2-methylphenoxy)acetyl}amino}benzoic acid;
 2-{{(3,4-difluorophenoxy)acetyl}amino}benzoic acid;
 2-(4-chlorophenoxy)-N-[2-(1H-tetrazol-5-yl)phenyl]acetamide;
 2-{{N-(3,4-dibromophenyl)-N-methylglycyl}amino}benzoic acid;
 2-{{N-(2,5-dibromophenyl)glycyl}amino}benzoic acid;
 2-{{(2-cyanophenoxy)acetyl}amino}benzoic acid;
 5-hydroxy-2-{{(2,4,5-trichlorophenoxy)acetyl}amino}benzoic acid;
 2-{{(2-chloro-4,5-dimethylphenoxy)acetyl}amino}benzoic acid;
 2-({[4-chloro-3-(trifluoromethyl)phenoxy]acetyl}amino}benzoic
 acid;
 2-{{(2-bromo-4-chloro-5-methylphenoxy)acetyl}amino}benzoic
 acid;
 2-{{(2-ethyl-4,5-dimethylphenoxy)acetyl}amino}benzoic acid;
 2-({[3,4-dichlorophenyl)sulfanyl]acetyl}amino}benzoic acid;
 2-({[4-chlorophenyl)sulfanyl]acetyl}amino}benzoic acid;
 2-{{(2-bromo-4,5-difluorophenoxy)acetyl}amino}benzoic acid;
 2-({[3-(trifluoromethyl)phenoxy]acetyl}amino}benzoic acid;

2-{{(2-bromo-4-chloro-5-methylphenoxy)acetyl}amino}-5-hydroxybenzoic acid;

2-{{(2,4,5-trifluorophenoxy)acetyl}amino}benzoic acid;

2-{{(3,5-dichlorophenoxy)acetyl}amino}-5-hydroxybenzoic acid;

2-{{(2,4,5-trichlorophenyl)thio}acetyl}amino}benzoic acid;

2-{{[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}benzoic acid;

2-{{(3,5-difluorophenoxy)acetyl}amino}benzoic acid;

2-{{(3,5-difluorophenoxy)acetyl}amino}-5-hydroxybenzoic acid;

2-{{(2-bromophenoxy)acetyl}amino}-5-hydroxybenzoic acid;

2-{{(2-chloro-6-methylphenoxy)acetyl}amino}benzoic acid;

2-{{(4-chloro-3-ethylphenoxy)acetyl}amino}benzoic acid;

2-{{[N-(2,4,5-trichlorophenyl)glycyl]amino}benzoic acid;

5-hydroxy-2-{{[N-(2,4,5-trichlorophenyl)glycyl]amino}benzoic acid;

2-{{(3-chloro-4-methylphenoxy)acetyl}amino}benzoic acid;

2-{{(3-chloro-4-methylphenoxy)acetyl}amino}-5-hydroxybenzoic acid;

2-{{(2-chloro-5-fluorophenoxy)acetyl}amino}benzoic acid;

2-{{(2-chloro-5-fluorophenoxy)acetyl}amino}-5-hydroxybenzoic acid;

2-{{(3-chloro-4-fluorophenoxy)acetyl}amino}benzoic acid;

2-{{(3-chloro-4-fluorophenoxy)acetyl}amino}-5-hydroxybenzoic acid;

2-{{(4-chloro-3-fluorophenoxy)acetyl}amino}benzoic acid;

2- {[N-(3,4-difluorophenyl)glycyl]amino} benzoic acid;
 2- {[N-(3,4-dichlorophenyl)glycyl]amino} benzoic acid;
 2- {[N-(2,5-dibromophenyl)glycyl]amino}-5-hydroxybenzoic acid;
 2- {[N-(4-chloro-2-fluorophenyl)glycyl]amino} benzoic acid;
 2- {[[(4-chloro-3-fluorophenoxy)acetyl]amino}-5-hydroxybenzoic
 acid;
 2- {[N-(2-fluoro-4-methylphenyl)glycyl]amino} benzoic acid;
 2- {[N-(3,4-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;
 2- {[N-(2,5-dichlorophenyl)glycyl]amino} benzoic acid;
 2- {[N-(2,5-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;
 2- {[N-(3,4-dichlorophenyl)-N-ethylglycyl]amino} benzoic acid;
 2- {[N-(3,4-dichlorophenyl)-N-ethylglycyl]amino}-5-
 hydroxybenzoic acid;
 2- {[N-(3,4-dichlorophenyl)-N-propylglycyl]amino} benzoic acid;
 2- {[N-(3,4-dichlorophenyl)-N-propylglycyl]amino}-5-
 hydroxybenzoic acid;
 2- {[N-(2,5-dichlorophenyl)-N-methylglycyl]amino}-5-
 hydroxybenzoic acid;
 2- {[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}-5-
 hydroxybenzoic acid;
 2- {[N-(3-chloro-4-fluorophenyl)glycyl]amino} benzoic acid;
 2- {[[(3,4,-dimethylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;
 2- {[[(2-chlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{{[(2-bromo-4-methylphenoxy)acetyl]amino}benzoic acid;
2-{{[(4-nitrophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
2-{{[2-(2-chloro-phenoxy)acetyl]amino}benzoic acid;
2-{{[(4-bromophenyl)methyl}{2-isopropyl-5-methylphenoxyacetyl]amino}benzoic acid;
2-{{[(4-cyclohexylphenoxy)acetyl]amino}benzoic acid; and
pharmaceutically acceptable salts thereof.


3. (Original) The method of claim 1 wherein the compound is selected from the group consisting of

2-{{[(2,4,5-trichlorophenoxy)acetyl]amino}benzoic acid;
2-{{[N-(2,5-dibromophenyl)glycyl]amino}-5-hydroxybenzoic acid;
2-{{[N-(3,4-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;
and pharmaceutically acceptable salts thereof.

4. (Original) The method of claim 1 wherein the compound is selected from the group consisting of

5-hydroxy-2-{{[(2,4,5-trichlorophenoxy)acetyl]amino}benzoic acid;
2-{{[(2-bromo-4-chloro-5-methylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;
2-{{[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}-5-hydroxybenzoic acid; and pharmaceutically acceptable salts thereof.

5. (Original) The method of claim 1 wherein the mammal is human.
6. (Original) The method of claim 5 wherein the composition is administered orally to said human.
7. (Original) The method of claim 6 wherein the compound is administered orally at a dose range of about 0.01 to 100 mg/kg from 1 to 6 times a day.
8. (Original) The method of claim 7 wherein the compound is administered orally at a dose range of about 0.1 to 10 mg/kg from 1 to 6 times a day.
9. (Original) The method of claim 8 wherein the compound is administered from 1 to 4 times a day.
10. (Original) The method of claim 5 wherein the composition is administered subcutaneously to said human.
11. (Previously Presented) A pharmaceutical composition for the treatment of hepatitis comprising a compound having the structure



and pharmaceutically acceptable salts thereof, wherein:

R₁, R₂, R₃, R₄ and R₅ are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, methoxy, nitro, C₂-C₄ alkenyl, cyano, and trifluoromethyl;

X is O, S, NH, or NR where R is a C₁-C₄ alkyl group;

W is CO₂H or 5- tetrazolyl;

Z is hydrogen or mono-methyl and

G is either OH, F, or hydrogen;

and a pharmaceutically acceptable carrier.

12. (Original) The composition of claim 11 wherein the compound is selected from the group consisting of

2-{[(2,4-dichlorophenoxy)acetyl]amino}benzoic acid;

2-{[(2,5-dimethylphenoxy)acetyl]amino}benzoic acid;

2-{[(2-ethoxy-5-Z-(2-propenyl)phenoxy)acetyl]amino}benzoic acid;

2-{[(2-bromo-5-fluorophenoxy)acetyl]amino}benzoic acid;

2-{[(2-methyl-5-nitrophenoxy)acetyl]amino}benzoic acid;

2-{[(2-fluoro-5-methylphenoxy)acetyl]amino}benzoic acid;

2-[2-(4-Bromo-phenoxy)-acetylamino]-benzoic acid;

2-[2-(3-Bromo-phenoxy)-acetylamino]-benzoic acid;

2-[2-(2-Bromo-phenoxy)-acetylamino]-benzoic acid;

2-[2-(4-Bromo-phenoxy)-propionylamino]-benzoic acid;

2-[2-(4-Bromo-phenylsulfanyl)-acetylamino]-benzoic acid;

2-[2-(4-Chloro-phenoxy)-acetylamino]-benzoic acid;
 2-[2-(4-Fluoro-phenoxy)-acetylamino]-benzoic acid;
 2-[[3-chlorophenoxy)acetyl]amino} benzoic acid;
 2-[[3-chlorophenoxy)acetyl]amino}-5-fluorobenzoic acid;
 2-[[3-chlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
 2-[[3,4-dimethylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;
 2-[[3-bromophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
 2-[[2S)-2-(4-chlorophenoxy)propanoyl]amino} benzoic acid;
 2-[[2,3-dichlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
 2-[[2,4,5-trichlorophenoxy)acetyl]amino} benzoic acid;
 2-[[2,4-dibromophenoxy)acetyl]amino} benzoic acid;
 2-[[2-chlorophenoxy)acetyl]amino} benzoic acid;
 2-[N-(3-bromophenyl)glycyl]amino} benzoic acid;
 2-[N-(4-bromo-3-chlorophenyl)-N-methylglycyl]amino} benzoic
 acid;
 2-[[4-chloro-2-methylphenoxy)acetyl]amino} benzoic acid;
 2-[[5-chloro-2-methylphenoxy)acetyl]amino} benzoic acid;
 2-[[3,4-difluorophenoxy)acetyl]amino} benzoic acid;
 2-(4-chlorophenoxy)-N-[2-(1H-tetrazol-5-yl)phenyl]acetamide;
 2-[N-(3,4-dibromophenyl)-N-methylglycyl]amino} benzoic acid;
 2-[N-(2,5-dibromophenyl)glycyl]amino} benzoic acid;
 2-[[2-cyanophenoxy)acetyl]amino} benzoic acid;
 5-hydroxy-2-[[2,4,5-trichlorophenoxy)acetyl]amino} benzoic acid;

2-{{{(2-chloro-4,5-dimethylphenoxy)acetyl}amino}benzoic acid;
 2-({[4-chloro-3-(trifluoromethyl)phenoxy]acetyl}amino}benzoic
 acid;
 2-{{{(2-bromo-4-chloro-5-methylphenoxy)acetyl}amino}benzoic
 acid;
 2-{{{(2-ethyl-4,5-dimethylphenoxy)acetyl}amino}benzoic acid;
 2-({[3,4-dichlorophenyl)sulfanyl]acetyl}amino}benzoic acid;
 2-({[4-chlorophenyl)sulfanyl]acetyl}amino}benzoic acid;
 2-{{{(2-bromo-4,5-difluorophenoxy)acetyl}amino}benzoic acid;
 2-({[3-(trifluoromethyl)phenoxy]acetyl}amino}benzoic acid;
 2-{{{(2-bromo-4-chloro-5-methylphenoxy)acetyl}amino}-5-
 hydroxybenzoic acid;
 2-{{{(2,4,5-trifluorophenoxy)acetyl}amino}benzoic acid;
 2-({[3,5-dichlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
 2-({[2,4,5-trichlorophenyl)thio]acetyl}amino)benzoic acid;
 2-{{[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}benzoic acid;
 2-({[3,5-difluorophenoxy)acetyl]amino}benzoic acid;
 2-({[3,5-difluorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
 2-{{{(2-bromophenoxy)acetyl}amino}-5-hydroxybenzoic acid;
 2-{{{(2-chloro-6-methylphenoxy)acetyl}amino}benzoic acid;
 2-{{{(4-chloro-3-ethylphenoxy)acetyl}amino}benzoic acid;
 2-{{[N-(2,4,5-trichlorophenyl)glycyl]amino}benzoic acid;
 5-hydroxy-2-{{[N-(2,4,5-trichlorophenyl)glycyl]amino}benzoic acid;

2-{[(3-chloro-4-methylphenoxy)acetyl]amino}benzoic acid;
2-{[(3-chloro-4-methylphenoxy)acetyl]amino}-5-hydroxybenzoic
acid;

2-{[(2-chloro-5-fluorophenoxy)acetyl]amino}benzoic acid;
2-{[(2-chloro-5-fluorophenoxy)acetyl]amino}-5-hydroxybenzoic
acid;

2-{[(3-chloro-4-fluorophenoxy)acetyl]amino}benzoic acid;
2-{[(3-chloro-4-fluorophenoxy)acetyl]amino}-5-hydroxybenzoic
acid;

2-{[(4-chloro-3-fluorophenoxy)acetyl]amino}benzoic acid;
2-{[N-(3,4-difluorophenyl)glycyl]amino}benzoic acid;
2-{[N-(3,4-dichlorophenyl)glycyl]amino}benzoic acid;
2-{[N-(2,5-dibromophenyl)glycyl]amino}-5-hydroxybenzoic acid;
2-{[N-(4-chloro-2-fluorophenyl)glycyl]amino}benzoic acid;
2-{[(4-chloro-3-fluorophenoxy)acetyl]amino}-5-hydroxybenzoic
acid;

2-{[N-(2-fluoro-4-methylphenyl)glycyl]amino}benzoic acid;
2-{[N-(3,4-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;
2-{[N-(2,5-dichlorophenyl)glycyl]amino}benzoic acid;
2-{[N-(2,5-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;
2-{[N-(3,4-dichlorophenyl)-N-ethylglycyl]amino}benzoic acid;
2-{[N-(3,4-dichlorophenyl)-N-ethylglycyl]amino}-5-
hydroxybenzoic acid;

2- {[N-(3,4-dichlorophenyl)-N-propylglycyl]amino} benzoic acid;
 2- {[N-(3,4-dichlorophenyl)-N-propylglycyl]amino}-5-
 hydroxybenzoic acid;
 2- {[N-(2,5-dichlorophenyl)-N-methylglycyl]amino}-5-
 hydroxybenzoic acid;
 2- {[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}-5-
 hydroxybenzoic acid;
 2- {[N-(3-chloro-4-fluorophenyl)glycyl]amino} benzoic acid;
 2- {[[(3,4,-dimethylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;
 2- {[[(2-chlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
 2- {[[(2-bromo-4-methylphenoxy)acetyl]amino} benzoic acid;
 2- {[[(4-nitrophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
 2- {[2-(2-chloro-phenoxy)acetyl]amino} benzoic acid;
 2- {[[(4-bromophenyl)methyl] {2-isopropyl-5-
 methylphenoxyacetyl}amino] benzoic acid;
 2- {[[(4-cyclohexylphenoxy)acetyl]amino} benzoic acid, and
 pharmaceutically acceptable salts thereof.

13. (Original) The composition of claim 11 wherein the compound is
 selected from the group consisting of

2- {[[(2,4,5-trichlorophenoxy)acetyl]amino} benzoic acid;
 2- {[N-(2,5-dibromophenyl)glycyl]amino}-5-hydroxybenzoic acid;
 2- {[N-(3,4-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;

and pharmaceutically acceptable salts thereof.


14. (Original) The composition of claim 11 wherein the compound is selected from the group consisting of

5-hydroxy-2-{[(2,4,5-trichlorophenoxy)acetyl]amino}benzoic acid;

2-{[(2-bromo-4-chloro-5-methylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}-5-hydroxybenzoic acid; and pharmaceutically acceptable salts thereof.

15. (Original) A method of treating hepatitis C in a mammal having symptoms of hepatitis C comprising administering to said mammal an effective amount of a pharmaceutical composition comprising a compound having the structure



(II)

and pharmaceutically acceptable salts thereof, wherein:

R_1 , R_2 , R_3 , R_4 and R_5 are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, methoxy, nitro, C_2 - C_4 alkenyl, cyano, and trifluoromethyl;

X is O, S, NH, or NR where R is a C₁-C₄ alkyl group;

Y is CO₂H or CO₂CH₃;

Z is hydrogen or mono-methyl;

G₁ is OH, F, methoxy or hydrogen; and

G₂ is either OH, Cl, methoxy or hydrogen.

16. (Original) The method of claim 15 wherein the compound is selected from the group consisting of

2-[(4-chlorophenoxy)acetylamino]-benzoic acid methyl ester;

2-[(4-methoxyphenoxy)acetylamino]-benzoic acid methyl ester;

2-[(4-cyclohexylphenoxy)acetylamino]-4,5-dimethoxybenzoic acid;

2-[(2-phenoxy)propionylamino]-4-hydroxybenzoic acid;


2-[[3,4,-dimethylphenoxy)acetyl]amino}-4-hydroxybenzoic acid;

2-[(3-methylphenoxy)acetylamino]-4,5-dimethoxybenzoic acid;

2-[(3-methylphenoxy)acetylamino]-4-chlorobenzoic acid; and

pharmaceutically acceptable salts thereof.

17. (Currently Amended) A pharmaceutical composition for the treatment of hepatitis comprising a compound having the structure



(II)

and pharmaceutically acceptable salts thereof, wherein:

R_1 , R_2 , R_3 , R_4 and R_5 are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, methoxy, nitro, C_2 - C_4 alkenyl, cyano, and trifluoromethyl;

X is O, S, NH, or NR where R is a C_1 - C_4 alkyl group;

Y is CO_2H or CO_2CH_3 ;

Z is hydrogen or mono-methyl;

G_1 is OH, F, methoxy or hydrogen; and

G_2 is either OH, Cl, methoxy or hydrogen;

and a pharmaceutically acceptable carrier.

18. (Currently Amended) The pharmaceutical composition of claim 17 wherein the compound is selected from the group consisting of

2-[(4-chlorophenoxy)acetylamino] benzoic acid methyl ester;

2-[(4-methoxyphenoxy)acetylamino] benzoic acid methyl ester;

2-[(4-cyclohexylphenoxy)acetylamino]-4,5-dimethoxybenzoic acid;

2-[(2-phenoxy)propionylamino]-4-hydroxybenzoic acid;

2-[[3,4,-dimethylphenoxy)acetyl]amino}-4-hydroxybenzoic acid;
2-[(3-methylphenoxy)acetylamino]-4,5-dimethoxybenzoic acid;
2-[(3-methylphenoxy)acetylamino]-4-chlorobenzoic acid; and
pharmaceutically acceptable salts thereof.